



## Senzime AB (publ) launches new website

**Uppsala, February 7, 2017. Senzime AB (publ) launches new website.** The new website is reworked with a new design, functionality and technical platform to successfully communicate the company's technology and development towards all stakeholders.

"As we approach the market and engage distributors, we see a growing need for a modern website with the ability to reach out both scientifically and marketwise, while also opening up the possibility to manage the dialogue with our distributors in a simple and direct way. This is another important step towards building a global leader in patient monitoring." says Lena Söderström, CEO of Senzime AB.

### **For further information, please contact:**

Pernilla Abrahamsson, Marketing and Sales Director Senzime

Tel: 070-37 37 472, e-post: [pernilla.abrahamsson@senzime.com](mailto:pernilla.abrahamsson@senzime.com)

### **TO THE EDITORS**

#### **About Senzime**

Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients' neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of \$10 billion. The company's shares are listed on AktieTorget (ATORG: SEZI) [www.senzime.com](http://www.senzime.com)